Fate Therapeutics Inc [NASDAQ: FATE] loss -9.05% on the last trading session, reaching $3.62 price per share at the time.
If compared to the average trading volume of 2.24M shares, FATE reached a trading volume of 3316700 in the most recent trading day, which is why market watchdogs consider the stock to be active.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Here is what top equities market gurus are saying about Fate Therapeutics Inc [FATE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FATE shares is $6.71 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FATE stock is a recommendation set at 2.56. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Fate Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on June 17, 2024. While these analysts kept the previous recommendation, Wells Fargo raised their target price to Equal Weight. The new note on the price target was released on March 27, 2023, representing the official price target for Fate Therapeutics Inc stock. Previously, the target price had yet another drop from $115 to $7, while H.C. Wainwright kept a Neutral rating on FATE stock. On January 06, 2023, analysts decreased their price target for FATE shares from 42 to 7.
The Average True Range (ATR) for Fate Therapeutics Inc is set at 0.49, with the Price to Sales ratio for FATE stock in the period of the last 12 months amounting to 63.59. The Price to Book ratio for the last quarter was 0.97, with the Price to Cash per share for the same quarter was set at 3.37.
Trading performance analysis for FATE stock
Fate Therapeutics Inc [FATE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -25.82. With this latest performance, FATE shares gained by 16.03% in over the last four-week period, additionally sinking by -34.89% over the last 6 months – not to mention a rise of 2.55% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FATE stock in for the last two-week period is set at 38.55, with the RSI for the last a single of trading hit 31.06, and the three-weeks RSI is set at 42.23 for Fate Therapeutics Inc [FATE]. The present Moving Average for the last 50 days of trading for this stock 3.96, while it was recorded at 4.14 for the last single week of trading, and 4.46 for the last 200 days.
Fate Therapeutics Inc [FATE]: A deeper dive into fundamental analysis
Fate Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.69 and a Current Ratio set at 8.69.
An analysis of Institutional ownership at Fate Therapeutics Inc [FATE]
The top three institutional holders of FATE stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.5034%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $178.43 billion in FATE stocks shares; and BERKSHIRE HATHAWAY INC, currently with $135.36 billion in FATE stock with ownership which is approximately 5.1238%.
